Melanoma: a prototype of cancer-testis antigen-expressing malignancies
Melanoma is the first malignancy in which expression and immunogenicity of cancer-testis antigens (CTAs) have been documented. Several CTAs have been shown to be expressed in melanoma samples especially those with metastatic potential. Many of them have been shown to exert oncogenic effects through...
Gespeichert in:
| Veröffentlicht in: | Immunotherapy 2017-10, Vol.9 (13), p.1103-1113 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1113 |
|---|---|
| container_issue | 13 |
| container_start_page | 1103 |
| container_title | Immunotherapy |
| container_volume | 9 |
| creator | Faramarzi, Sepideh Ghafouri-Fard, Soudeh |
| description | Melanoma is the first malignancy in which expression and immunogenicity of cancer-testis antigens (CTAs) have been documented. Several CTAs have been shown to be expressed in melanoma samples especially those with metastatic potential. Many of them have been shown to exert oncogenic effects through modulation of essential pathways involved in melanoma. The crucial role of CTAs in the pathogenesis of melanoma, the high prevalence of expression of CTA panels in melanoma and the presence of spontaneous as well as inducible immune responses against CTAs in melanoma patients potentiate CTAs as immunotherapeutic targets. Numerous clinical trials are now ongoing to evaluate CTA-based immunotherapeutic effects in melanoma patient's survival. NY-ESO-1 and MAGE antigens have the most promising results up to now. |
| doi_str_mv | 10.2217/imt-2017-0091 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2323439966</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2323439966</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-89a4384f9328722285f9ddfd499a67de8ba324cd8212d130e3a8107259418653</originalsourceid><addsrcrecordid>eNp1kD1PwzAQhi0EoqUwsqJIzAZ_JbbZUEUBqYilA5vlJnblqnGC7Uj03-MqpRuTz9Jz7909ANxi9EAI5o-uTZAgzCFCEp-BKeYlgpwxcX6q6dcEXMW4RahivGKXYEIkooRTPgWLD7PTvmv1U6GLPnSpS_veFJ0tau1rE2AyMblYaJ_cxnhofvpgYnR-U7R65zY-U87Ea3Bh9S6am-M7A6vFy2r-Bpefr-_z5yWsKccJCqkZFcxKSgQnhIjSyqaxDZNSV7wxYq0pYXUjCCYNpshQLTDipJQMi6qkM3A_xuZNv4e8mdp2Q_B5oiKUUEalrKpMwZGqQxdjMFb1wbU67BVG6iBNZWnqIE0dpGX-7pg6rFvTnOg_SxmQI2CHNOTz88XZjRp_ucPVzpt_wn8B8oV6Zw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2323439966</pqid></control><display><type>article</type><title>Melanoma: a prototype of cancer-testis antigen-expressing malignancies</title><source>MEDLINE</source><source>PubMed Central</source><creator>Faramarzi, Sepideh ; Ghafouri-Fard, Soudeh</creator><creatorcontrib>Faramarzi, Sepideh ; Ghafouri-Fard, Soudeh</creatorcontrib><description>Melanoma is the first malignancy in which expression and immunogenicity of cancer-testis antigens (CTAs) have been documented. Several CTAs have been shown to be expressed in melanoma samples especially those with metastatic potential. Many of them have been shown to exert oncogenic effects through modulation of essential pathways involved in melanoma. The crucial role of CTAs in the pathogenesis of melanoma, the high prevalence of expression of CTA panels in melanoma and the presence of spontaneous as well as inducible immune responses against CTAs in melanoma patients potentiate CTAs as immunotherapeutic targets. Numerous clinical trials are now ongoing to evaluate CTA-based immunotherapeutic effects in melanoma patient's survival. NY-ESO-1 and MAGE antigens have the most promising results up to now.</description><identifier>ISSN: 1750-743X</identifier><identifier>EISSN: 1750-7448</identifier><identifier>DOI: 10.2217/imt-2017-0091</identifier><identifier>PMID: 29032737</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Animals ; Antigens ; Antigens, Neoplasm - immunology ; Antigens, Neoplasm - metabolism ; Biomarkers ; Biomarkers, Tumor - metabolism ; Breast cancer ; cancer-testis antigen ; Cell adhesion & migration ; Cell division ; Cell growth ; Clinical trials ; Clinical Trials as Topic ; Gene Expression Regulation, Neoplastic ; Humans ; Immune response ; Immunogenicity ; Immunotherapy ; Immunotherapy - methods ; Lymphocytes ; Malignancy ; Melanoma ; Melanoma - genetics ; Melanoma - metabolism ; Melanoma - therapy ; Melanoma-Specific Antigens - immunology ; Melanoma-Specific Antigens - metabolism ; Membrane Proteins - immunology ; Membrane Proteins - metabolism ; Metastases ; Metastasis ; Mutation ; Neoplasm Metastasis ; Peptides ; Skin cancer ; Vaccines</subject><ispartof>Immunotherapy, 2017-10, Vol.9 (13), p.1103-1113</ispartof><rights>2017 Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd Oct 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-89a4384f9328722285f9ddfd499a67de8ba324cd8212d130e3a8107259418653</citedby><cites>FETCH-LOGICAL-c371t-89a4384f9328722285f9ddfd499a67de8ba324cd8212d130e3a8107259418653</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29032737$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Faramarzi, Sepideh</creatorcontrib><creatorcontrib>Ghafouri-Fard, Soudeh</creatorcontrib><title>Melanoma: a prototype of cancer-testis antigen-expressing malignancies</title><title>Immunotherapy</title><addtitle>Immunotherapy</addtitle><description>Melanoma is the first malignancy in which expression and immunogenicity of cancer-testis antigens (CTAs) have been documented. Several CTAs have been shown to be expressed in melanoma samples especially those with metastatic potential. Many of them have been shown to exert oncogenic effects through modulation of essential pathways involved in melanoma. The crucial role of CTAs in the pathogenesis of melanoma, the high prevalence of expression of CTA panels in melanoma and the presence of spontaneous as well as inducible immune responses against CTAs in melanoma patients potentiate CTAs as immunotherapeutic targets. Numerous clinical trials are now ongoing to evaluate CTA-based immunotherapeutic effects in melanoma patient's survival. NY-ESO-1 and MAGE antigens have the most promising results up to now.</description><subject>Animals</subject><subject>Antigens</subject><subject>Antigens, Neoplasm - immunology</subject><subject>Antigens, Neoplasm - metabolism</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Breast cancer</subject><subject>cancer-testis antigen</subject><subject>Cell adhesion & migration</subject><subject>Cell division</subject><subject>Cell growth</subject><subject>Clinical trials</subject><subject>Clinical Trials as Topic</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immunogenicity</subject><subject>Immunotherapy</subject><subject>Immunotherapy - methods</subject><subject>Lymphocytes</subject><subject>Malignancy</subject><subject>Melanoma</subject><subject>Melanoma - genetics</subject><subject>Melanoma - metabolism</subject><subject>Melanoma - therapy</subject><subject>Melanoma-Specific Antigens - immunology</subject><subject>Melanoma-Specific Antigens - metabolism</subject><subject>Membrane Proteins - immunology</subject><subject>Membrane Proteins - metabolism</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Mutation</subject><subject>Neoplasm Metastasis</subject><subject>Peptides</subject><subject>Skin cancer</subject><subject>Vaccines</subject><issn>1750-743X</issn><issn>1750-7448</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kD1PwzAQhi0EoqUwsqJIzAZ_JbbZUEUBqYilA5vlJnblqnGC7Uj03-MqpRuTz9Jz7909ANxi9EAI5o-uTZAgzCFCEp-BKeYlgpwxcX6q6dcEXMW4RahivGKXYEIkooRTPgWLD7PTvmv1U6GLPnSpS_veFJ0tau1rE2AyMblYaJ_cxnhofvpgYnR-U7R65zY-U87Ea3Bh9S6am-M7A6vFy2r-Bpefr-_z5yWsKccJCqkZFcxKSgQnhIjSyqaxDZNSV7wxYq0pYXUjCCYNpshQLTDipJQMi6qkM3A_xuZNv4e8mdp2Q_B5oiKUUEalrKpMwZGqQxdjMFb1wbU67BVG6iBNZWnqIE0dpGX-7pg6rFvTnOg_SxmQI2CHNOTz88XZjRp_ucPVzpt_wn8B8oV6Zw</recordid><startdate>20171001</startdate><enddate>20171001</enddate><creator>Faramarzi, Sepideh</creator><creator>Ghafouri-Fard, Soudeh</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20171001</creationdate><title>Melanoma: a prototype of cancer-testis antigen-expressing malignancies</title><author>Faramarzi, Sepideh ; Ghafouri-Fard, Soudeh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-89a4384f9328722285f9ddfd499a67de8ba324cd8212d130e3a8107259418653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Antigens</topic><topic>Antigens, Neoplasm - immunology</topic><topic>Antigens, Neoplasm - metabolism</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Breast cancer</topic><topic>cancer-testis antigen</topic><topic>Cell adhesion & migration</topic><topic>Cell division</topic><topic>Cell growth</topic><topic>Clinical trials</topic><topic>Clinical Trials as Topic</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immunogenicity</topic><topic>Immunotherapy</topic><topic>Immunotherapy - methods</topic><topic>Lymphocytes</topic><topic>Malignancy</topic><topic>Melanoma</topic><topic>Melanoma - genetics</topic><topic>Melanoma - metabolism</topic><topic>Melanoma - therapy</topic><topic>Melanoma-Specific Antigens - immunology</topic><topic>Melanoma-Specific Antigens - metabolism</topic><topic>Membrane Proteins - immunology</topic><topic>Membrane Proteins - metabolism</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Mutation</topic><topic>Neoplasm Metastasis</topic><topic>Peptides</topic><topic>Skin cancer</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Faramarzi, Sepideh</creatorcontrib><creatorcontrib>Ghafouri-Fard, Soudeh</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Faramarzi, Sepideh</au><au>Ghafouri-Fard, Soudeh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Melanoma: a prototype of cancer-testis antigen-expressing malignancies</atitle><jtitle>Immunotherapy</jtitle><addtitle>Immunotherapy</addtitle><date>2017-10-01</date><risdate>2017</risdate><volume>9</volume><issue>13</issue><spage>1103</spage><epage>1113</epage><pages>1103-1113</pages><issn>1750-743X</issn><eissn>1750-7448</eissn><abstract>Melanoma is the first malignancy in which expression and immunogenicity of cancer-testis antigens (CTAs) have been documented. Several CTAs have been shown to be expressed in melanoma samples especially those with metastatic potential. Many of them have been shown to exert oncogenic effects through modulation of essential pathways involved in melanoma. The crucial role of CTAs in the pathogenesis of melanoma, the high prevalence of expression of CTA panels in melanoma and the presence of spontaneous as well as inducible immune responses against CTAs in melanoma patients potentiate CTAs as immunotherapeutic targets. Numerous clinical trials are now ongoing to evaluate CTA-based immunotherapeutic effects in melanoma patient's survival. NY-ESO-1 and MAGE antigens have the most promising results up to now.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>29032737</pmid><doi>10.2217/imt-2017-0091</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1750-743X |
| ispartof | Immunotherapy, 2017-10, Vol.9 (13), p.1103-1113 |
| issn | 1750-743X 1750-7448 |
| language | eng |
| recordid | cdi_proquest_journals_2323439966 |
| source | MEDLINE; PubMed Central |
| subjects | Animals Antigens Antigens, Neoplasm - immunology Antigens, Neoplasm - metabolism Biomarkers Biomarkers, Tumor - metabolism Breast cancer cancer-testis antigen Cell adhesion & migration Cell division Cell growth Clinical trials Clinical Trials as Topic Gene Expression Regulation, Neoplastic Humans Immune response Immunogenicity Immunotherapy Immunotherapy - methods Lymphocytes Malignancy Melanoma Melanoma - genetics Melanoma - metabolism Melanoma - therapy Melanoma-Specific Antigens - immunology Melanoma-Specific Antigens - metabolism Membrane Proteins - immunology Membrane Proteins - metabolism Metastases Metastasis Mutation Neoplasm Metastasis Peptides Skin cancer Vaccines |
| title | Melanoma: a prototype of cancer-testis antigen-expressing malignancies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T04%3A45%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Melanoma:%20a%20prototype%20of%20cancer-testis%20antigen-expressing%20malignancies&rft.jtitle=Immunotherapy&rft.au=Faramarzi,%20Sepideh&rft.date=2017-10-01&rft.volume=9&rft.issue=13&rft.spage=1103&rft.epage=1113&rft.pages=1103-1113&rft.issn=1750-743X&rft.eissn=1750-7448&rft_id=info:doi/10.2217/imt-2017-0091&rft_dat=%3Cproquest_cross%3E2323439966%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2323439966&rft_id=info:pmid/29032737&rfr_iscdi=true |